Analysts Set Affimed (NASDAQ:AFMD) Price Target at $13.50

Shares of Affimed (NASDAQ:AFMD) have been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $13.50.

AFMD has been the subject of several research reports. Stifel Nicolaus cut their target price on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research note on Friday, November 15th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Affimed in a research note on Tuesday, December 10th. Wells Fargo & Company decreased their target price on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th.

Institutional Investors Weigh In On Affimed

Several institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. raised its stake in shares of Affimed by 4.6% during the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the last quarter. Intellectus Partners LLC raised its position in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. FMR LLC raised its position in Affimed by 30.0% during the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock valued at $59,000 after purchasing an additional 4,086 shares during the last quarter. Jane Street Group LLC purchased a new stake in Affimed in the 3rd quarter worth approximately $44,000. Finally, Choreo LLC bought a new stake in shares of Affimed in the 2nd quarter worth approximately $54,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

Affimed Price Performance

AFMD opened at $1.19 on Tuesday. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The stock has a 50-day moving average price of $2.92 and a 200-day moving average price of $4.04. Affimed has a 12-month low of $1.14 and a 12-month high of $8.95.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.